Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Aurinia Pharmaceuticals Inc To Discuss Renal Biopsy Substudy Top-line Results Call Transcript

Apr 05, 2023 / 12:30PM GMT
Release Date Price: €9.03 (-1.85%)
Operator

Greetings, and welcome to the Aurinia Pharmaceuticals AURORA Renal Sub-study top line results webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the conference over to your host, Jamie Harrell, Investor Relations for Aurinia Pharmaceuticals. Thank you. You may begin.

Jamie Harrell

Thank you, operator, and thank you all for joining today's call and webcast to discuss the top line results from the AURORA renal sub-study. This morning, Aurinia issued a press release announcing the top line results from the AURORA 1 and AURORA 2 renal sub-study. For more information and to see the slides being shared on today's call, please refer to the Investor Relations Corporate Presentations section of the auriniapharma.com website.

Now during this call, Aurinia may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. Please note that all statements made during today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot